What remains to be investigated is whether sequestration of both B and T cells in SLE patients by an S1PR1-specific modulator can drive the same therapeutic benefit, as opposed to killing B cells directly, and whether engaging S1PR5 contributes to clinical benefit. This evidence concerns the gene S1PR1 and systemic lupus erythematosus.